{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T14:27:11Z","timestamp":1725460031259},"publisher-location":"Boston","reference-count":36,"publisher":"Kluwer Academic Publishers","isbn-type":[{"type":"print","value":"0306477572"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/0-306-48382-3_98","type":"book-chapter","created":{"date-parts":[[2006,2,18]],"date-time":"2006-02-18T20:57:40Z","timestamp":1140296260000},"page":"481-486","source":"Crossref","is-referenced-by-count":0,"title":["Beh\u00e7et\u2019s Syndrome: From Aetiology to Treatment"],"prefix":"10.1007","author":[{"given":"Richard J.","family":"Powell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"98_CR1","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z","volume":"42","author":"M.A. Frassantio","year":"1999","unstructured":"Frassantio, M.A., Dammacco, R., Cafforio, P., et al., 1999, The polarization of the immune response in Beh\u00e7et\u2019s disease. Arthritis Rheum. 42: 1967\u20131974.","journal-title":"Arthritis Rheum."},{"key":"98_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/b100540","volume-title":"Adamantiades-Beh\u00e7et\u2019s Disease","author":"Ch.C. Zouboulis","year":"2003","unstructured":"Zouboulis, Ch.C., K\u00f6tter, I., Djawari, D., et al., 2003, Current epidemiological data from the German registry of Adamantiades-Beh\u00e7et\u2019s disease. In Adamantiades-Beh\u00e7et\u2019s Disease (Ch.C. Zouboulis, ed.), Kluwer\/Plenum, London, pp. 43\u201348."},{"key":"98_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-3476(99)70333-1","volume":"135","author":"I. Kone-Paut","year":"1999","unstructured":"Kone-Paut, I., Geisler, I., Wechsler, B., et al., 1999, Familial aggregation in Beh\u00e7et\u2019s disease: High frequency in siblings and parents of paediatric probands. J. Pediatr. 135: 89\u201393.","journal-title":"J. Pediatr."},{"key":"98_CR4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/ard.59.8.622","volume":"50","author":"A. Gul","year":"2000","unstructured":"Gul, A., Inane, M., Ocal, L., et al., 2000, Familial aggregation of Beh\u00e7et\u2019s disease in Turkey. Ann. Rheum. Dis. 50: 622\u2013625.","journal-title":"Ann. Rheum. Dis."},{"key":"98_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.61.2.157","volume":"61","author":"R. Cohen","year":"2002","unstructured":"Cohen, R., Metzger, M., Nahir, T., et al., 2002, Association of the MIC-A gene and HLA-B51 with Beh\u00e7et\u2019s disease in Arabs and non-Ashkenazi Jews in Israel. Ann. Rheum. Dis. 61: 157\u2013160.","journal-title":"Ann. Rheum. Dis."},{"key":"98_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s002510050656","volume":"49","author":"G.R. Wallace","year":"1999","unstructured":"Wallace, G.R., Verity, D.H., Delamaine, L.J., et al., 1999, MIC-A allele profiles and HLA class I associations in Beh\u00e7et\u2019s disease. Immunogenetics 49: 613\u2013617.","journal-title":"Immunogenetics"},{"key":"98_CR7","first-page":"2693","volume":"44","author":"A. Gul","year":"2001","unstructured":"Gul, A., Hajeer, A.H., Worthington, J., et al., 2001, Linkage mapping of a novel susceptibility locus for Beh\u00e7et\u2019s disease to chromosome 6p22\u201323. Ann. Rheum. Dis. 44: 2693\u20132696.","journal-title":"Ann. Rheum. Dis."},{"key":"98_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(96)90868-5","volume":"347","author":"A. Hasan","year":"1996","unstructured":"Hasan, A., Fortune, F., Wilson, A., et al., 1996, Role of \u03b3\u03b4 T cells in pathogenesis and diagnosis of Beh\u00e7et\u2019s disease. Lancet 347: 789\u2013794.","journal-title":"Lancet"},{"key":"98_CR9","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"S. Yurdakul","year":"2001","unstructured":"Yurdakul, S., Mat, C., Tuzun, Y., et al., 2001, A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum. 44: 2686\u20132692.","journal-title":"Arthritis Rheum."},{"key":"98_CR10","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","volume":"39","author":"M. Calguneri","year":"1996","unstructured":"Calguneri, M., Kiraz, S., Ertenli, I., et al., 1996, The effect of prophylactic penicllin treatment on the course of arthritis episodes in patients with Beh\u00e7et\u2019s disease. Arthritis Rheum. 39: 2062\u20132065.","journal-title":"Arthritis Rheum."},{"key":"98_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H. Yazici","year":"1990","unstructured":"Yazici, H., Pazarli, H., Barnes, C.G., et al., 1990, A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N. Engl. J. Med. 322: 281\u2013285.","journal-title":"N. Engl. J. Med."},{"key":"98_CR12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/art.1780400425","volume":"40","author":"V. Hamuryudan","year":"1997","unstructured":"Hamuryudan, V., Ozyazgan, Y., Hizli, N., et al., 1997, Azathioprine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum. 40: 760\u2013774.","journal-title":"Arthritis Rheum."},{"key":"98_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1076\/ocii.9.4.219.3957","volume":"9","author":"B.A. Mudun","year":"2001","unstructured":"Mudun, B.A., Ergen, A., Ipcioglu, S.U., et al., 2001, Short-term chlorambucil for refractory uveitis in Beh\u00e7et\u2019s disease. Ocul. Immunol. Inflamm. 9: 219\u2013229.","journal-title":"Ocul. Immunol. Inflamm."},{"key":"98_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713689008999414","volume":"9","author":"M. Diaz-Llopis","year":"1990","unstructured":"Diaz-Llopis, M., Cervera, M., and Menezo, J.L., 1990, Cyclosporin A treatment of Beh\u00e7et\u2019s disease: A long-term study. Cur. Eye Res. 9: 17\u201323.","journal-title":"Cur. Eye Res."},{"key":"98_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","volume":"106","author":"C.M.L. Sloper","year":"1999","unstructured":"Sloper, C.M.L., Powell, R.J., and Dua, H.S., 1999, Tacrolimus (FK 506) in the treatment of posterior uveitis refractory to cyclopsorine. Ophthalmology 106: 723\u2013728.","journal-title":"Ophthalmology"},{"key":"98_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E. Alpsoy","year":"2002","unstructured":"Alpsoy, E., Durusoy, C., Yilmaz, E., et al., 2002, Interferon alfa-2a in the treatment of Beh\u00e7et disease: A randomized placebo-controlled and double-blind study. Arch. Dermatol. 138: 467\u2013471.","journal-title":"Arch. Dermatol."},{"key":"98_CR17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0190-9622(91)70156-V","volume":"24","author":"J.L. Jorizzo","year":"1991","unstructured":"Jorizzo, J.L., White, W.L., Wise, C.M., et al., 1991 Low dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Beh\u00e7et\u2019s disease. J. Am. Acad. Dermatol. 24: 973\u2013978.","journal-title":"J. Am. Acad. Dermatol."},{"key":"98_CR18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-124-10-199605150-00005","volume":"124","author":"K. Yasui","year":"1996","unstructured":"Yasui, K., Ohta, K., Kobayashi, M., et al., 1996, Successful treatment of Beh\u00e7et disease with pentoxifylline. Ann. Intern. Med. 124: 891\u2013893.","journal-title":"Ann. Intern. Med."},{"key":"98_CR19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.1780250621","volume":"25","author":"M. Hamza","year":"1982","unstructured":"Hamza, M., Ayed, K., and Ayed, H.B., 1982, Treatment of Beh\u00e7et\u2019s disease with levamisole. Arthritis Rheum. 25: 714\u2013715.","journal-title":"Arthritis Rheum."},{"key":"98_CR20","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","volume":"276","author":"J.A. Keifer","year":"2001","unstructured":"Keifer, J.A., Guttridge, D.C., Ashburner, B.P., et al., 2001, Inhibition of NF\u03baB activity by thalidomide through suppression of I\u03baB kinase activity. J. Biol. Chem. 276: 22382\u20137.","journal-title":"J. Biol. Chem."},{"key":"98_CR21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V. Hamuryudan","year":"1998","unstructured":"Hamuryudan, V., Mat, C., Saip, S., et al., 1998, Thalidomide in the treatment of mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placeob-controlled trial. Ann. Intern. Med. 128: 443\u2013450.","journal-title":"Ann. Intern. Med."},{"key":"98_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","volume":"119","author":"S. Bastuji-Garin","year":"2002","unstructured":"Bastuji-Garin, S., Ochonicky, S., Bouche, P., et al, 2002, Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatological patients. J. Invest. Dermatol. 119: 1020\u20131026.","journal-title":"J. Invest. Dermatol."},{"key":"98_CR23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/pgmj.70.830.901","volume":"70","author":"R.J. Powell","year":"1994","unstructured":"Powell, R.J., and Gardner-Medwin, J.M.M., 1994, Guideline for the clinical use and dispensing of thalidomide. Postgrad. Med. J. 70: 901\u2013904.","journal-title":"Postgrad. Med. J."},{"key":"98_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","volume":"21","author":"J.B. Zeldis","year":"1999","unstructured":"Zeldis, J.B., Williams, B.A., Thomas, S.D., et al., 1999, S.T.E.P.S.\u2122: A comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. 21: 319\u2013330.","journal-title":"Clin. Ther."},{"key":"98_CR25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00001622-200211000-00008","volume":"14","author":"N. Raje","year":"2002","unstructured":"Raje, N., and Anderson, K.C., 2002, Thalidomide and immunomodulatory drugs as cancer therapy. Cur. Opin. Oncol. 14: 635\u2013640.","journal-title":"Cur. Opin. Oncol."},{"key":"98_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1046\/j.1365-2249.2000.01332.x","volume":"121","author":"M. Guckian","year":"2000","unstructured":"Guckian, M., Dransfield, I., Hay, P. et al., 2000, Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin. Exp. Immunol. 121: 472\u2013479.","journal-title":"Clin. Exp. Immunol."},{"key":"98_CR27","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"M.J. Elliott","year":"1994","unstructured":"Elliott, M.J., Maini, R.N., Feldmann, M., et al., 1994, Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105\u20131110.","journal-title":"Lancet"},{"key":"98_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"S.B. Hanauer","year":"2002","unstructured":"Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al., 2002, Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial. Lancet 359: 1541\u20131549.","journal-title":"Lancet"},{"key":"98_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00063030-200216020-00005","volume":"16","author":"G.M. Keating","year":"2002","unstructured":"Keating, G.M., and Perry, C.M., 2002, Infliximab: An updated review of its use in Crohn\u2019s disease and rheumatoid arthritis. BioDrugs 16: 111\u2013148.","journal-title":"BioDrugs"},{"key":"98_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J. Keane","year":"2001","unstructured":"Keane, J., Gershon, S., Wise, R., et al., 2001, Tuberculosis associated with infliximab. A tumour necrosis factor alpha neutralising agent. N. Engl. J. Med. 345: 1098\u20131104.","journal-title":"N. Engl. J. Med."},{"key":"98_CR31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","volume":"346","author":"F.G. Rosa De","year":"2002","unstructured":"De Rosa, F.G., Bonora, S., and Di Perri, G., 2002, Tuberculosis and treatment with infliximab. N. Engl. J. Med. 346: 623\u2013626.","journal-title":"N. Engl. J. Med."},{"key":"98_CR32","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","volume":"358","author":"S. Munoz-Fernandez","year":"2001","unstructured":"Munoz-Fernandez, S., Hidalgo, V., Fernandez-Melon, J., et al., 2001, Effect of infliximab on threatening panuveitis in Behcet\u2019s disease. Lancet 358: 1644.","journal-title":"Lancet"},{"key":"98_CR33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","volume":"120","author":"P.V. Hassard","year":"2001","unstructured":"Hassard, P.V., Binder, S.W., Nelson, V., et al., 2001, Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et\u2019s disease: A case report. Gastroenterology 120: 995\u2013999.","journal-title":"Gastroenterology"},{"key":"98_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/ard.60.6.637","volume":"60","author":"P.H. Goossens","year":"2001","unstructured":"Goossens, P.H., Verburg, R.J., and Breedveld, F.C., 2001, Remission of Beh\u00e7et\u2019s syndrome with tumor necrosis factor \u03b1 blocking therapy. Ann. Rheum. Dis. 60: 637\u2013638.","journal-title":"Ann. Rheum. Dis."},{"key":"98_CR35","first-page":"55","volume":"2","author":"M.S. Buckland","year":"2002","unstructured":"Buckland, M.S., O\u2019Grady, C., and Helbert, M.R., 2002, Infliximab in the treatment of soft tissue inflammation of Beh\u00e7et\u2019s disease. CPD Bull. Immunol. Allergy 2: 55\u201357.","journal-title":"CPD Bull. Immunol. Allergy"},{"key":"98_CR36","unstructured":"Melikoglu, M., Fresko, I., Mat, C., et al., 2002, A double blind placebo controlled trial of etanercept on the mucocutaneous lesions of Beh\u00e7et\u2019s syndrome. In Programme and Abstracts. 10th International Conference on Beh\u00e7et\u2019s Disease, Berlin, p. 68."}],"container-title":["Advances in Experimental Medicine and Biology","Adamantiades-Beh\u00e7et\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/0-306-48382-3_98.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T04:31:26Z","timestamp":1619497886000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/0-306-48382-3_98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["0306477572"],"references-count":36,"URL":"https:\/\/doi.org\/10.1007\/0-306-48382-3_98","relation":{},"subject":[]}}